The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Getting on top of the tuberculosis epidemic requires renewed attention, and bringing HIV out of isolation.
Opportunities to increase access to the hepatitis C cure exist – but strong political will is needed and many countries are failing to benefit from cheaper generics.
In their first treatment update since 2016, the World Health Organization (WHO) adopts a ‘treat all’ approach for hepatitis C, guided by the success of the HIV treatment experience.
Despite the huge human and economic toll, research into hepatitis B remains drastically underfunded, and was recently alikened to a neglected tropical disease. But hope for a cure is growing.
Increasing numbers of people co-infected with HIV and hepatitis C (HCV) are accessing treatment for HCV as antivirals become more effective – but challenges beyond increasing access, remain.
Interim clinical trial results offer hope to people living with hepatitis C who stand to benefit from reduced price treatment, including the 2.3 million people who have HIV co-infection.
In the run up to World Tuberculosis (TB) Day (March 24), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization reveal the region is off- target to end TB by 2030.
New research shows that food insecurity can impact treatment outcomes for people living with HIV and hepatitis C (HCV) co-infection.
As progress continues to fall short of the fast approaching 2030 targets, the World Health Organisation (WHO) calls for accelerated, multi-sectoral action against tuberculosis – the leading killer of people living with HIV.
Untreated depression could seriously compromise treatment outcomes for people living with HIV, warn critics.